首页 | 本学科首页   官方微博 | 高级检索  
     

司库奇尤单抗治疗红皮病型银屑病一例并文献复习
引用本文:朱慧英,施仲香,曹楠,田洪青,杜东红. 司库奇尤单抗治疗红皮病型银屑病一例并文献复习[J]. 中国麻风皮肤病杂志, 2021, 37(10): 653-656. DOI: 10.12144/zgmfskin202110653
作者姓名:朱慧英  施仲香  曹楠  田洪青  杜东红
作者单位:1山东第一医科大学(山东省医学科学院),济南,250002;2山东第一医科大学附属皮肤病医院(山东省皮肤病医院,山东省皮肤病性病防治研究所),济南,250022
摘    要:报道一例司库奇尤单抗治疗红皮病型银屑病治疗效果并复习相关文献.41岁红皮病型银屑病男性患者,在排除肝炎、结核的基础上,经知情同意后,给予司库奇尤单抗标准方案:0~4周每周皮下注射300 mg,随后每4周注射300 mg.在第4周达到PASI 75,第8周达到PASI 100.随访32周未见明显复发及不良反应.

关 键 词:红皮病型银屑病  司库奇尤单抗  银屑病  生物制剂  抗IL-17A

Secukinumab in the treatment of erythrodermic psoriasis: a case report and literature review
ZHU Huiying,SHI Zhongxiang,CAO Nan,TIAN Hongqing,DU Donghong. Secukinumab in the treatment of erythrodermic psoriasis: a case report and literature review[J]. China Journal of Leprosy and Skin Diseases, 2021, 37(10): 653-656. DOI: 10.12144/zgmfskin202110653
Authors:ZHU Huiying  SHI Zhongxiang  CAO Nan  TIAN Hongqing  DU Donghong
Affiliation:1 Shandong First Medical University (Shandong Academy of Medical Sciences), Jinan 250002, China; 2 Shandong Provincial Hospital for Skin Diseases & Shandong Provincial Institute of Dermatology and Venereology, Shandong First Medical University, Jinan 250022, China
Abstract:A 41-year-old male with erythrodermic psoriasis treated with secukinumab was reported and the related literature were reviewed. After excluding hepatitis and tuberculosis, the patient was given the secukinumab with informed consent. The dose was 300 mg subcutaneously once a week in the first 4 weeks, then 300 mg once every four weeks. The PASI achieved to 75% at week 4 and 100% at week 8. There was no recurrence and adverse events after 32 weeks follow-up.
Keywords:erythrodermic psoriasis  secukinumab  psoriasis  biologics  anti-IL17A  
本文献已被 CNKI 等数据库收录!
点击此处可从《中国麻风皮肤病杂志》浏览原始摘要信息
点击此处可从《中国麻风皮肤病杂志》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号